Royalty Pharma Earns Its Profits The Slow Way
This article was originally published in The Pink Sheet Daily
Executive Summary
Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.
You may also be interested in...
Royalty Pharma Nears Biopharma Record Take With $2.18bn IPO
Company specializing in trading upfront cash for downstream earnings makes its public debut with largest IPO of 2020, and the second largest ever in biopharma.
Deals of the Week Plays Favorites: Our Deals Of The Year Winners!
We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.
Biopharma Dealmaking Quarterly Statistics, Q3 2013
Biopharma financing in Q3 2013 totaled $4.6 billion, a 58% drop from the second quarter; Perrigo’s $8.3 billion acquisition of Elan made up more than half of the M&A dollar value; and marketed products made up the majority of licensed products.